Business Description
Alivus Life Sciences Ltd
ISIN : INE03Q201024
Total Employee Number:
2,220Compare
Compare
Traded in other countries / regions
543322.India Index Membership
NIFTY 500NIFTY 500 IPO Date
2021-08-06Description
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.35 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.07 | |||||
Interest Coverage | 134.39 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 15.01 | |||||
Beneish M-Score | -2.18 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.5 | |||||
3-Year EBITDA Growth Rate | 7.3 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year FCF Growth Rate | 21.6 | |||||
3-Year Book Growth Rate | 15.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.78 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.71 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.19 | |||||
9-Day RSI | 56.8 | |||||
14-Day RSI | 58.7 | |||||
3-1 Month Momentum % | -4.05 | |||||
6-1 Month Momentum % | 10.93 | |||||
12-1 Month Momentum % | -0.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.21 | |||||
Quick Ratio | 3.85 | |||||
Cash Ratio | 1.6 | |||||
Days Inventory | 238.23 | |||||
Days Sales Outstanding | 145.21 | |||||
Days Payable | 133.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.44 | |||||
Dividend Payout Ratio | 0.11 | |||||
3-Year Dividend Growth Rate | -45.9 | |||||
Forward Dividend Yield % | 0.44 | |||||
5-Year Yield-on-Cost % | 0.44 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 0.2 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.2 | |||||
Operating Margin % | 28.29 | |||||
Net Margin % | 22.12 | |||||
EBITDA Margin % | 32.61 | |||||
FCF Margin % | 10.12 | |||||
OCF Margin % | 22.16 | |||||
ROE % | 18.48 | |||||
ROA % | 15.35 | |||||
ROIC % | 20.96 | |||||
3-Year ROIIC % | 11.33 | |||||
ROC (Joel Greenblatt) % | 30.67 | |||||
ROCE % | 23.73 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 24.6 | |||||
Forward PE Ratio | 16.48 | |||||
PE Ratio without NRI | 23.79 | |||||
Price-to-Owner-Earnings | 36.24 | |||||
PEG Ratio | 4.1 | |||||
PS Ratio | 5.45 | |||||
PB Ratio | 4.16 | |||||
Price-to-Tangible-Book | 4.2 | |||||
Price-to-Free-Cash-Flow | 53.76 | |||||
Price-to-Operating-Cash-Flow | 24.55 | |||||
EV-to-EBIT | 17.27 | |||||
EV-to-Forward-EBIT | 1.5 | |||||
EV-to-EBITDA | 15.72 | |||||
EV-to-Forward-EBITDA | 1.25 | |||||
EV-to-Revenue | 5.13 | |||||
EV-to-Forward-Revenue | 0.39 | |||||
EV-to-FCF | 52.03 | |||||
Price-to-GF-Value | 1.12 | |||||
Price-to-Projected-FCF | 2.39 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.85 | |||||
Price-to-Graham-Number | 2.11 | |||||
| Price-to-Net-Current-Asset-Value | 6.94 | |||||
| Price-to-Net-Cash | 84.46 | |||||
Earnings Yield (Greenblatt) % | 5.79 | |||||
FCF Yield % | 1.87 | |||||
Forward Rate of Return (Yacktman) % | 7.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alivus Life Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 25,518.32 | ||
| EPS (TTM) (₹) | 45.9 | ||
| Beta | 0.5249 | ||
| 3-Year Sharpe Ratio | 0.64 | ||
| 3-Year Sortino Ratio | 1.18 | ||
| Volatility % | 18.14 | ||
| 14-Day RSI | 58.7 | ||
| 14-Day ATR (₹) | 40.074057 | ||
| 20-Day SMA (₹) | 1097.525 | ||
| 12-1 Month Momentum % | -0.96 | ||
| 52-Week Range (₹) | 819 - 1193.9 | ||
| Shares Outstanding (Mil) | 122.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alivus Life Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alivus Life Sciences Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-06 08:30 | In 121 days | ||
| Second quarter earnings results for 2027 | 2026-11-06 | In 120 days | ||
| General meeting for 2026 | 2026-09-08 15:00 | In 62 days | ||
| Annual report for 2026 | 2026-08-12 | In 34 days | ||
| First quarter earnings conference call for 2027 | 2026-07-31 08:30 | In 23 days | ||
| First quarter earnings results for 2027 | 2026-07-31 | In 22 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-15 08:30 | 1,064.10 (-3.18%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-15 | 1,064.10 (-3.18%) | ||
| Third quarter earnings conference call for 2026 | 2026-01-22 18:00 | 861.30 (+0.70%) | ||
| Third quarter earnings results for 2026 | 2026-01-22 | 861.30 (+0.70%) |
Show
Entries
Alivus Life Sciences Ltd Frequently Asked Questions
What is Alivus Life Sciences Ltd(NSE:ALIVUS)'s stock price today?
The current price of NSE:ALIVUS is ₹1130.10. The 52 week high of NSE:ALIVUS is ₹1193.90 and 52 week low is ₹819.00.
When is next earnings date of Alivus Life Sciences Ltd(NSE:ALIVUS)?
The next earnings date of Alivus Life Sciences Ltd(NSE:ALIVUS) is 2026-07-31 Est..
Does Alivus Life Sciences Ltd(NSE:ALIVUS) pay dividends? If so, how much?
The Dividend Yield %  of Alivus Life Sciences Ltd(NSE:ALIVUS) is 0.44% (As of Today), Highest Dividend Payout Ratio of Alivus Life Sciences Ltd(NSE:ALIVUS) was 0.83. The lowest was 0.11. And the median was 0.44. The  Forward Dividend Yield % of Alivus Life Sciences Ltd(NSE:ALIVUS) is 0.44%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Alivus Life Sciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers